ArticleContraception and reproductive medicine2025
Progestin-only pretreatment enhances follicular synchronization and embryo development: a three-arm retrospective cohort study in GnRH antagonist cycles.
Article in Contraception and reproductive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormonal pretreatment prior to controlled ovarian stimulation (COS) in assisted reproductive technology (ART) is widely used to improve follicular synchronization and schedule flexibility. However, the comparative impact of different pretreatment strategies—progestin-only, combined oral contraceptive pills (COCP), and no pretreatment—on follicular dynamics and clinical outcomes remains unclear.
methodsIn this retrospective cohort study, 240 patients undergoing their first IVF/ICSI cycle with a GnRH antagonist protocol and recombinant FSH monotherapy were analyzed. Participants were divided into three groups: progestin-only pretreatment (P group), COCP pretreatment (COCP group), and no pretreatment (control group). Baseline characteristics, follicular development, embryo quality, and cumulative reproductive outcomes were compared. Levene’s test was used to assess follicular size variability, and multivariable regression analyses were performed to adjust for confounding variables.
resultsThe P group demonstrated significantly improved follicular synchronization, as evidenced by the lowest variability in the ratio of follicles ≥ 18 mm to ≥ 14 mm. Embryological outcomes were superior in the P group, with higher oocyte maturation rate (p = 0.040), fertilization rate (p = 0.038), and number of good-quality blastocysts (p = 0.015) compared to the other groups. The blastocyst development rate was also significantly greater (p = 0.029). Although cumulative live birth rate (CLBR) did not reach statistical significance, a trend toward higher CLBR was observed in the P group (87.0%) compared to COCP (72.0%) and control (75.2%).
conclusionProgestin-only pretreatment leads to superior follicular synchronization and improved embryo developmental potential in GnRH antagonist IVF/ICSI cycles. These benefits may enhance ART efficiency and contribute to improved cumulative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.